Producer
Bausch + Lomb
Eye-health company (contact lenses, surgical, pharma). Markets Adato Sil-Ol 5000 (5,000 cSt silicone oil tamponade, U.S.) and the Oxane 1300/5700 silicone oil line (Europe).
2
Inputs supplied
2
Goods downstream
0
Facilities
0
Stories
What they make
2 inputs Bausch + Lomb supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Bausch + Lomb makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Vision Care (Contact Lenses & Solutions)
48%Ophthalmic Pharmaceuticals
30%Surgical
22%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Bausch + Lomb's Adato Sil-Ol 5000 vitreoretinal silicone oil and their Viscoat ophthalmic viscoelastic both rely on PDMS (polydimethylsiloxane) chemistry — the same base polymer as breast implant shells and fill, medical device surface coatings, personal care products (hair conditioner slip agents), and industrial release agents. The silicone supply chain for B+L's eye surgery consumables runs through Dow, Shin-Etsu Chemical, and Momentive — the same suppliers that make medical-grade silicone for breast augmentation, joint prosthetic coatings, and dialysis tubing. A silicone monomer disruption simultaneously affects retinal surgery, cosmetic implants, and a wide range of medical device supply chains through shared chemical feedstock.
Bausch + Lomb ↗Origin2024
Bausch + Lomb was founded in 1853 in Rochester, New York by John Jacob Bausch and Henry Lomb, selling optical goods in an era when German optical imports dominated. Bausch + Lomb became famous for inventing Ray-Ban sunglasses (1937, for US Army Air Corps pilots — the original aviator sunglass to reduce altitude glare), the SoftLens contact lens (1971 — first FDA-approved soft contact lens), and manufacturing the optics for the Hubble Space Telescope's corrective COSTAR instrument (after the original mirror's spherical aberration was discovered). In 2013, Valeant Pharmaceuticals acquired B+L for $8.7B and spent years cutting R&D and raising drug prices, nearly destroying the brand's reputation. Bausch + Lomb was separated from Bausch Health (Valeant's renamed successor) as an independent public company in May 2022.
Bausch + Lomb ↗Concentration2024
The global ophthalmic pharmaceutical and surgical supply chain has three primary players — Alcon, Johnson & Johnson Vision (AMO), and Bausch + Lomb — who collectively dominate IOLs, surgical equipment, contact lenses, and prescription eye drugs. All three are US-regulated (FDA) or Swiss-regulated (Swissmedic) companies with US manufacturing presence, but their supply chains for silicone polymers, hyaluronic acid, and specialty ophthalmic drug excipients are globally sourced. Global ophthalmology is the most concentrated specialty in all of medical devices: three companies control the materials used in virtually every procedure treating the most common chronic disease (refractive error) and the most common surgery (cataract) for the world's aging population.
Bausch + Lomb ↗